• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cameron Health’s FDA date is good news for Boston Scientific

Cameron Health’s FDA date is good news for Boston Scientific

March 19, 2012 By MassDevice staff

leadless ICD

Cameron Health landed an April date with the FDA’s circulatory devices panel to review a pre-market approval application for its lead-free subcutaneous implantable cardioverter defibrillator, or S-ICD.

The S-ICD system, unlike traditional ICDs, sits just beneath the skin and does not rely on wires relayed through blood vessels and connected to the heart in order to provide heart rhythm therapy.

The device, which has been the only lead-free cardiac rhythm implant on the market since winning CE Mark approval in the European Union in 2009, will get the FDA treatment on April 26, according to the watchdog agency.

That’s good news for Boston Scientific (NYSE:BSX), which earlier this month said it would pay up to $1.35 billion for Cameron Health.

Cameron filed its PMA in December 2011, making the quick FDA turnaround a positive sign for its steward-to-be. Nevertheless the news didn’t win much love from Wall Street today, where BSX shares were down 7¢ to $6.05 as of about 3 p.m.

"To us, FDA scheduling a panel to review the lead-less ICD so urgently … could suggest basically 2 things," analysts at Leerink Swann wrote in a note to investors. "(1) FDA must believe this is important new technology – particularly in the context of ongoing transvenous lead performance concerns (which the S-ICD aims to avoid), (2) FDA must have a basically positive bias toward the technology."

Either way, that’s a windfall for med-tech titan Boston Scientific and a possible setback for Edwards Lifesciences (NYSE:EW), which is not now likely to win its own panel date in April to review the "high-risk" patient group, cohort A, in its Sapien transcatheter heart valve PMA bid.

"Based on the FDA’s tentative panel meeting calendar, the next possible date for an EW Sapien panel now appears May 24," according to the analysts. "Clearly, the longer cohort A approval drags out, the more risk to numbers and the greater the likelihood of further downward estimate revisions."

EW shares were down 1% to $70.75 in late afternoon trading.

The April panel will also consider HeartWare’s implantable rotary blood pump, according to the FDA notice.

Filed Under: Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA) Tagged With: Boston Scientific, Cameron Health Inc., Cardiac Rhythm Management, Edwards Lifesciences, HeartWare International Inc.

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy